Home › Biomarkers › ESR1 mutation
ESR1 mutation testing: what it means for you
Waiting on test results can feel like one more hard thing, for you and the people who love you. Here's what the ESR1 mutation test looks for and how it can help your care team pick the treatment most likely to work for you.
ℹ️ General information to help you and your loved ones talk with your care team, not medical advice. Read our disclaimer.
Matters most in: Breast cancer
The quick guide
What the test looks for: Changes in the ESR1 gene, which carries the instructions for the estrogen receptor. They usually show up after hormone therapy (especially aromatase inhibitors) in advanced hormone receptor-positive breast cancer, and are often found with a blood test (liquid biopsy).
Why it matters
An ESR1 change can help the cancer keep growing even when estrogen is lowered. It doesn't mean you're out of options: newer hormone pills were made to work against these cancers. Because ESR1 changes can appear over time, your team may retest if the cancer grows.
Treatments it can point to
- Newer hormone pills (oral SERDs), Orserdu (elacestrant) or Inluriyo (imlunestrant), FDA-approved for advanced ER-positive, HER2-negative breast cancer with an ESR1 change that grew after at least one hormone therapy (Orserdu (elacestrant))
Only your care team can say which treatment fits you. Drug approvals depend on cancer type, stage and prior treatment.
Tissue vs. blood testing
Usually blood (liquid biopsy), sometimes tissue. Testing is often repeated when advanced cancer grows on treatment.
Most tests use a piece of tumor tissue from a biopsy or surgery. Some can also use a blood sample (a 'liquid biopsy') that looks for tumor DNA floating in the blood. Blood tests are easier and faster, but they can miss a change that a tissue test would find, so a negative blood test is often followed by a tissue test.
❓ Questions you and your loved ones can ask
- Should I have an ESR1 blood test now that my cancer has grown?
- Would an oral SERD be right for me?
- When will my results be back, and will treatment wait for them?
- Will my insurance cover this test?
Written by the Cancer Side Effects Guide team from FDA labels and leading cancer centers. Not medical advice. · Last updated: October 15, 2026 · How we write
Sources
Last updated: October 15, 2026. We summarize these sources in our own words.
- FDA label: Orserdu (DailyMed)
- FDA: Approval of imlunestrant (Inluriyo)
- NCI: Breast Cancer Treatment (PDQ)
- NCI: Biomarker Testing for Cancer Treatment
- FDA: List of Cleared or Approved Companion Diagnostic Devices
- NCCN Guidelines for Patients: Invasive Breast Cancer, 2026
- NCCN Guidelines for Patients: Ductal Carcinoma in Situ (Stage 0 Breast Cancer), 2026
- NCCN Guidelines for Patients: Metastatic Breast Cancer, 2026
- NCCN Guidelines for Patients: Inflammatory Breast Cancer, 2026